Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Julio C B, Moraes"'
Autor:
Clovis A. Silva, Ana C. Medeiros-Ribeiro, Leonard V. K. Kupa, Emily F. N. Yuki, Sandra G. Pasoto, Carla G. S. Saad, Solange R. G. Fusco, Rosa M. R. Pereira, Samuel K. Shinjo, Ari S. R. Halpern, Eduardo F. Borba, Fernando H. C. Souza, Lissiane K. N. Guedes, Renata Miossi, Karina R. Bonfiglioli, Diogo S. Domiciano, Andrea Y. Shimabuco, Danieli C. O. Andrade, Luciana P. C. Seguro, Ricardo Fuller, Percival D. Sampaio-Barros, Ana P. L. Assad, Julio C. B. Moraes, Claudia Goldenstein-Schainberg, Henrique A. M. Giardini, Henrique C. Silva, Victor A. O. Martins, Lorena E. B. Villamarin, Renata S. Novellino, Lucas P. Sales, Carlo S. R. Araújo, Matheus S. R. Silva, Dilson M. N. Filho, Marta H. Lopes, Alberto J. S. Duarte, Esper G. Kallas, Nadia E. Aikawa, Eloisa Bonfa
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disea
Externí odkaz:
https://doaj.org/article/be9c68c40137469498e931f5f43c71ca
Autor:
Andrea Y. Shimabuco, Celio R. Gonçalves, Julio C. B. Moraes, Mariana G. Waisberg, Ana Cristina de M. Ribeiro, Percival D. Sampaio-Barros, Claudia Goldenstein-Schainberg, Eloisa Bonfa, Carla G. S. Saad
Publikováno v:
Advances in Rheumatology, Vol 58, Iss 1, Pp 1-8 (2018)
Abstract Objective To determine the clinical and demographic factors associated with disease remission and drug survival in patients with ankylosing spondylitis (AS) on TNF inhibitors. Methods Data from a longitudinal electronic database of AS patien
Externí odkaz:
https://doaj.org/article/d23661e93fb446118be34a6b1383bd7a
Autor:
Elaine P. Leon, Eloisa Bonfa, Carla G. S. Saad, Clovis A. Silva, Ana Cristina Medeiros-Ribeiro, Julio C. B. Moraes, Valquiria Garcia Dinis, V. S. T. Viana
Publikováno v:
Clinical Rheumatology. 39:1747-1755
To evaluate long-term effects on gamma-globulins and autoantibodies of abatacept (ABA) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. Eighteen RA patients undergoing abatacept (ABA-RA) and 18 age/sex-matched pat
Autor:
Clovis A. Silva, Ana C. Medeiros-Ribeiro, Leonard V. K. Kupa, Emily F. N. Yuki, Sandra G. Pasoto, Carla G. S. Saad, Solange R. G. Fusco, Rosa M. R. Pereira, Samuel K. Shinjo, Ari S. R. Halpern, Eduardo F. Borba, Fernando H. C. Souza, Lissiane K. N. Guedes, Renata Miossi, Karina R. Bonfiglioli, Diogo S. Domiciano, Andrea Y. Shimabuco, Danieli C. O. Andrade, Luciana P. C. Seguro, Ricardo Fuller, Percival D. Sampaio-Barros, Ana P. L. Assad, Julio C. B. Moraes, Claudia Goldenstein-Schainberg, Henrique A. M. Giardini, Henrique C. Silva, Victor A. O. Martins, Lorena E. B. Villamarin, Renata S. Novellino, Lucas P. Sales, Carlo S. R. Araújo, Matheus S. R. Silva, Dilson M. N. Filho, Marta H. Lopes, Alberto J. S. Duarte, Esper G. Kallas, Nadia E. Aikawa, Eloisa Bonfa
Publikováno v:
Nature communications. 13(1)
The determination of durability and vaccine-associated protection is essential for booster doses strategies, however data on the stability of SARS-CoV-2 immunity are scarce. Here we assess anti-SARS-CoV-2 immunogenicity decay and incident cases six m
Autor:
Percival Degrava Sampaio Barros, Sandra Gofinet Pasoto, Matheus Santos Rodrigues Silva, Renato Kenji Aoyama, Nádia Emi Aikawa, Cláudia Goldenstein Schainberg, Ana Cristina de Medeiros Ribeiro, Emily Figueiredo Neves Yuki, Tatiana do Nascimento Pedrosa, Carlo Scognamiglio Renner Araujo, Julio C. B. Moraes, Eloisa Silva Dutra de Oliveira Bonfa, Clovis Artur Silva, C. G. S. Saad
Publikováno v:
SBR 2021 Congresso Brasileiro de Reumatologia.
Autor:
Célio Roberto Gonçalves, Percival Degrava Sampaio Barros, Julio C. B. Moraes, Lucas Brandão Araujo da Silva, Nestor Barreto-Neto, Ana Cristina de Medeiros Ribeiro, C. G. S. Saad, Claudia Goldeinstein Schainberg
Publikováno v:
Anais do Congresso Brasileiro de Reumatologia 2020.
Autor:
Eloisa Bonfa, Karina Bonfiglioli, Ana Cristina de Medeiros Ribeiro, Julio C. B. Moraes, Thiago Trevisan, Andrea Yukie Shimabuco, Valquiria Garcia Dinis, Carla G. S. Saad
Publikováno v:
Anais do Congresso Brasileiro de Reumatologia 2020.
Autor:
Emily Figueiredo Neves Yuki, Renata Miossi, Ana Cristina Medeiros-Ribeiro, Leandro Lara do Prado, Karina Bonfiglioli, Michele Remião Ugolini-Lopes, Percival D. Sampaio-Barros, Julio C. B. Moraes, Célio Roberto Gonçalves, C. G. S. Saad, Claudia Goldenstein-Schainberg, Andrea Yukie Shimabuco, Fernando Henrique Carlos de Souza, Eloisa Bonfa
Publikováno v:
Clinics, Vol 75 (2020)
Clinics
Clinics, Volume: 75, Article number: e1870, Published: 11 NOV 2020
Clinics
Clinics, Volume: 75, Article number: e1870, Published: 11 NOV 2020
Objectives To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis f
Autor:
Julio C. B. Moraes, Ivanio Alves Pereira, Hellen M.S. Carvalho, David C. Titton, Izaias Pereira da Costa, Geraldo da Rocha Castelar Pinheiro, José Roberto Silva Miranda, Maria F L Cunha, Rogério de Melo Costa Pinto, Paulo Louzada-Junior, Roberto Acayaba de Toledo, Manoel Barros Bertolo, Claiton Viegas Brenol, Roberto Ranza, Washington A. Bianchi, B. Stadler, José Caetano Macieira, Miguel Ángel Descalzo, Mariana Cecconi, Ângela Luzia Branco Pinto Duarte, Marlene Freire, Valeria Valim, Vander Fernandes, Ieda Maria Magalhães Laurindo, Gláucio Ricardo Werner de Castro
Publikováno v:
Journal of Clinical Rheumatology
BACKGROUND The safety profile of biologic drugs might present substantial regional differences. Since 2009, the Brazilian Society of Rheumatology has maintained BIOBADABRASIL (Brazilian Registry for Biologic Drugs), a registry for monitoring of biolo
Autor:
Samuel Katsuyuki Shinjo, Julio C. B. Moraes, Eloisa Bonfa, Renata Miossi, Fernando Henrique Carlos de Souza
Publikováno v:
Advances in Rheumatology, Vol 58, Iss 1, Pp 1-6 (2018)
Background Interpretation of rituximab efficacy for refractory idiopathic inflammatory myopathies (IIM) is hampered by the absence of a uniform definition of refractory myositis and clinical response. Therefore, rigorous criteria of refractoriness, t